Edison Scientific
Category: AI in Biotech / Drug Discovery
An AI-powered research platform that deploys autonomous 'AI Scientists' to accelerate scientific discovery by automating complex tasks such as literature synthesis, hypothesis generation, and experimental design. Edison Scientific was founded in 2025. The company is led by Sam Rodriques. Based in San Francisco Bay Area. Total funding raised: $70.0M. Latest round: Seed Round ($70.0M, Dec 2025). Key investors include Spark Capital, Triatomic Capital, Pillar VC, Susa Ventures, Striker Venture Partners, Hawktail VC, Olive VC.
- Founded
- 2025
- Headquarters
- San Francisco Bay Area
- Total funding
- $70.0M
Value proposition
Dramatically reduces the time and cost of scientific R&D by enabling AI agents to perform months of research work in a matter of hours, automating the entire loop from hypothesis to data analysis.
Products and solutions
Edison Platform (Core R&D Automation), Kosmos (Autonomous AI Scientist Agent), PaperQA3 (Multimodal Deep Research Agent for Science), Literature Synthesis & Hypothesis Generation Tools, Molecular Design & Data Analysis Modules
Unique value
Developed 'Kosmos', an AI agent capable of autonomously conducting end-to-end scientific research, including coordinating multiple sub-agents to execute complex workflows without human intervention.
Target customer
Pharmaceutical companies, biotechnology firms, and academic research institutions
Industries served
Life Sciences, Biotechnology, Pharmaceuticals, Scientific Research
Technology advantage
Leverages a proprietary structured world model that allows AI agents to plan and execute scientific tasks with high reliability. As a commercial spinout from the non-profit FutureHouse, it benefits from deep academic roots and exclusive IP access.
How they differentiate
Edison differentiates by deploying 'Kosmos', a fully autonomous AI agent capable of end-to-end research rather than just predictive molecular modeling. Unlike Sakana AI's generalist 'AI Scientist', Edison is vertically integrated specifically for wet-lab biology and clinical workflows.
Main competitors
Sakana AI, Isomorphic Labs, Recursion Pharmaceuticals
Key partnerships
FutureHouse, Spark Capital, Triatomic Capital, Incyte Corporation
Notable customers
Incyte Corporation, Undisclosed major pharmaceutical companies
Major milestones
May 2025: Initial launch of the AI research platform (under FutureHouse), Nov 2025: Officially spun out from non-profit FutureHouse as a commercial entity, Dec 2025: Raised $70M Seed round co-led by Spark Capital and Triatomic Capital, Feb 2026: Released PaperQA3, a frontier multimodal deep research agent for science, Feb 2026: Released LABBench2 benchmark for measuring AI in biology research, May 2026: Robin AI Scientist published in Nature, May 2026: Announced strategic partnership with Incyte Corporation
Growth metrics
Valued at $250M post-money; reported 'overwhelming inbound interest' from major pharmaceutical companies.
Market positioning
First-mover in 'Autonomous AI Scientists' for commercial R&D; positioning as a full-stack research partner rather than a SaaS tool provider.
Geographic focus
North America (San Francisco Bay Area)
Patents and IP
Proprietary 'AI Scientist' algorithms and autonomous agent architectures
About Sam Rodriques
Co-founder of FutureHouse; former group leader at the Francis Crick Institute; physicist and bioengineer with inventions in transcriptomics, brain mapping, and gene therapy
Latest news about Edison Scientific
More AI in Biotech / Drug Discovery companies
Official website: https://edisonscientific.com
